CL2019003091A1 - Terapia de combinación. - Google Patents

Terapia de combinación.

Info

Publication number
CL2019003091A1
CL2019003091A1 CL2019003091A CL2019003091A CL2019003091A1 CL 2019003091 A1 CL2019003091 A1 CL 2019003091A1 CL 2019003091 A CL2019003091 A CL 2019003091A CL 2019003091 A CL2019003091 A CL 2019003091A CL 2019003091 A1 CL2019003091 A1 CL 2019003091A1
Authority
CL
Chile
Prior art keywords
combination
proliferative disease
treatment
subject
same
Prior art date
Application number
CL2019003091A
Other languages
English (en)
Inventor
Vesselina Cooke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019003091A1 publication Critical patent/CL2019003091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMBINACIÓN FARMACÉUTICA QUE COMPRENDE (A) UN INHIBIDOR DE RAF CONFORME LO DEFINIDO EN LA PRESENTE, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y (B) UN INHIBIDOR DE MEK, PARTICULARMENTE TRAMETINIB, PARTICULARMENTE PARA USO EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA. LA PRESENTE INVENCIÓN ADEMÁS SE REFIERE A USOS DE ESTA COMBINACIÓN PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA; A MÉTODOS DE TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA EN UN SUJETO QUE LO NECESITE QUE COMPRENDEN ADMINISTRAR A DICHO SUJETO UNA CANTIDAD CONJUNTAMENTE TERAPÉUTICAMENTE EFECTIVA DE DICHA COMBINACIÓN; AL USO DE TAL COMBINACIÓN PARA EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA; A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TAL COMBINACIÓN Y A ENVASES COMERCIALES PARA LAS MISMAS.
CL2019003091A 2017-05-02 2019-10-28 Terapia de combinación. CL2019003091A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500108P 2017-05-02 2017-05-02
US201862656423P 2018-04-12 2018-04-12

Publications (1)

Publication Number Publication Date
CL2019003091A1 true CL2019003091A1 (es) 2020-02-07

Family

ID=62218018

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003091A CL2019003091A1 (es) 2017-05-02 2019-10-28 Terapia de combinación.

Country Status (18)

Country Link
US (2) US11266653B2 (es)
EP (2) EP3618875B1 (es)
JP (2) JP7309614B2 (es)
KR (2) KR20240032157A (es)
CN (1) CN110494166B (es)
AU (1) AU2018262891B2 (es)
BR (1) BR112019022511A2 (es)
CA (1) CA3057969A1 (es)
CL (1) CL2019003091A1 (es)
DK (1) DK3618875T3 (es)
ES (1) ES2952265T3 (es)
FI (1) FI3618875T3 (es)
IL (1) IL270224B1 (es)
MX (1) MX2019012884A (es)
PL (1) PL3618875T3 (es)
PT (1) PT3618875T (es)
TW (1) TWI798218B (es)
WO (1) WO2018203219A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3665302A4 (en) * 2017-08-11 2021-04-28 Curematch, Inc. COMBINED MEDICINAL PRODUCTS AGAINST MULTIPLE MUTATIONS IN CANCER
KR20210105388A (ko) 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
US20230226030A1 (en) * 2020-02-18 2023-07-20 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
EP4115907A1 (en) * 2020-02-27 2023-01-11 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
JP2023525100A (ja) * 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
US20230321110A1 (en) * 2020-08-31 2023-10-12 Novartis Ag Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
WO2023166345A2 (en) 2022-03-02 2023-09-07 Novartis Ag Precision therapy for the treatment of cancer
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024088275A1 (zh) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 一种萘酰胺化合物治疗耐药性肿瘤的用途
CN117919235A (zh) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 一种萘酰胺化合物治疗kras突变相关疾病的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
RS52670B (en) 2004-06-11 2013-06-28 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP3981408A1 (en) 2012-09-04 2022-04-13 Novartis AG Dabrafenib and trametinib in a method of adjuvant cancer treatment
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
BR112019005046A2 (pt) * 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk

Also Published As

Publication number Publication date
CN110494166A (zh) 2019-11-22
JP7309614B2 (ja) 2023-07-18
US20200246346A1 (en) 2020-08-06
RU2019134757A3 (es) 2021-08-17
CN110494166B (zh) 2022-11-08
US11266653B2 (en) 2022-03-08
AU2018262891A1 (en) 2019-10-17
US20220143036A1 (en) 2022-05-12
JP2020518568A (ja) 2020-06-25
DK3618875T3 (da) 2023-07-10
WO2018203219A1 (en) 2018-11-08
IL270224B1 (en) 2024-04-01
EP4272740A1 (en) 2023-11-08
KR20240032157A (ko) 2024-03-08
TW201842914A (zh) 2018-12-16
CA3057969A1 (en) 2018-11-08
RU2019134757A (ru) 2021-06-02
EP3618875B1 (en) 2023-04-05
BR112019022511A2 (pt) 2020-05-12
IL270224A (es) 2019-12-31
ES2952265T3 (es) 2023-10-30
KR102641827B1 (ko) 2024-03-04
PL3618875T3 (pl) 2023-10-23
TWI798218B (zh) 2023-04-11
KR20190141164A (ko) 2019-12-23
JP2023145467A (ja) 2023-10-11
EP3618875A1 (en) 2020-03-11
AU2018262891B2 (en) 2021-04-01
FI3618875T3 (fi) 2023-07-04
PT3618875T (pt) 2023-08-07
MX2019012884A (es) 2020-01-14

Similar Documents

Publication Publication Date Title
CL2019003091A1 (es) Terapia de combinación.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
DOP2019000201A (es) Compuestos inhibidores del vih
NI201700032A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CO2017012381A2 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares